Cargando…

Reduction in PSA messenger-RNA expression and clinical recurrence in patients with prostatic cancer undergoing neoadjuvant therapy before radical prostatectomy

BACKGROUND: We assessed the incidence of micro-metastases at surgical margins (SM) and pelvic lymph nodes (LN) in patients submitted to radical retropubic prostatectomy (RP) after neoadjuvant therapy (NT) or to RP alone. We compared traditional staging to molecular detection of PSA using Taqman-base...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grasso, Marco, Lania, Caterina, Blanco, Salvatore, Baruffi, Marco, Mocellin, Simone
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC419380/ https://www.ncbi.nlm.nih.gov/pubmed/15104791 http://dx.doi.org/10.1186/1479-5876-2-13

Ejemplares similares

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

The natural history of a delayed detectable PSA after radical prostatectomy
por: Szymaniak, Julie A., et al.
Publicado: (2023)

"Ejaculatory disorders and α(1)-adrenoceptor antagonists therapy: clinical and experimental researches"
por: Grasso, Marco, et al.
Publicado: (2006)

PSA mass as a marker of prostate cancer progression after radical prostatectomy
por: Bryniarski, Piotr, et al.
Publicado: (2011)

Heterophilic Antibodies Resulting in False Positive Elevation of PSA After Radical Prostatectomy
por: Asha, Wafa, et al.
Publicado: (2023)

Preservation of Cavernosal Erectile Function after Soft Penile Prosthesis Implant in Peyronie's Disease: Long-Term Followup
por: Grasso, Marco, et al.
Publicado: (2008)

Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy
por: Cheng, Yung-Ting, et al.
Publicado: (2020)

Effect of Neoadjuvant Hormonal Therapy on the Postoperative Course for Patients Undergoing Robot-Assisted Radical Prostatectomy
por: Farzat, Mahmoud, et al.
Publicado: (2023)

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy
por: Kang, Yong Jin, et al.
Publicado: (2017)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
por: Sasaki, Takeshi, et al.
Publicado: (2021)

Neoadjuvant Chemohormonal Therapy in Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis
por: Ge, Qingyu, et al.
Publicado: (2022)

Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience
por: Quero, Laurent, et al.
Publicado: (2008)

Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival
por: Doherty, A P, et al.
Publicado: (2000)

Comparison of Pathological and Biochemical Outcomes after Radical Prostatectomy in Korean Patients with Serum PSA Ranges
por: Lee, Hye Won, et al.
Publicado: (2015)

Vesicoureteral Reflux in the Child with Lazy Bladder Syndrome: The Infrequent Voider
por: Grasso, Marco, et al.
Publicado: (2008)

Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL
por: Hinev, Alexander I., et al.
Publicado: (2012)

HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy
por: Zabalza, Cristina Villares, et al.
Publicado: (2015)

Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort
por: Tanguturi, Shyam K., et al.
Publicado: (2014)

Neoadjuvant chemotherapy before radical prostatectomy for locally advanced prostate cancer: Protocol for a systematic review and meta-analysis
por: Lin, Tianhai, et al.
Publicado: (2019)

Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy()
por: Minner, Sarah, et al.
Publicado: (2019)

(68)Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy
por: von Eyben, Finn Edler, et al.
Publicado: (2021)

Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
por: Naiki, Taku, et al.
Publicado: (2012)

Feasibility of Neoadjuvant Ad‐REIC Gene Therapy in Patients with High‐Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
por: Kumon, Hiromi, et al.
Publicado: (2015)

Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
por: Raggi, Daniele, et al.
Publicado: (2021)

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review
por: Yanagisawa, Takafumi, et al.
Publicado: (2023)

Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy
por: Maeda, Yoko, et al.
Publicado: (2016)

Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy
por: Ahn, Hyun Kyu, et al.
Publicado: (2020)

(68)Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy
por: Yuminaga, Yuigi, et al.
Publicado: (2021)

What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision-making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer?
por: Milecki, Piotr, et al.
Publicado: (2011)

[−2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report
por: De Luca, S., et al.
Publicado: (2016)

Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report
por: Zhuang, Junlong, et al.
Publicado: (2022)

Splenosis in patient undergoing robotic assisted laparoscopic radical prostatectomy
por: Sykes, Jennifer, et al.
Publicado: (2022)

Disease-specific outcomes of Radical Prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time
por: Andersen, Sigve, et al.
Publicado: (2014)

Dual-timing PSA as a biomarker for patients with salvage intensity modulated radiation therapy for biochemical failure after radical prostatectomy
por: Wang, Yu-Jen, et al.
Publicado: (2016)

The Role of (11)C-Choline-PET/CT-Guided Secondary Lymphadenectomy in Patients with PSA Failure after Radical Prostatectomy: Lessons Learned from Eight Cases
por: Martini, Thomas, et al.
Publicado: (2012)

Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy
por: Matsumoto, Kazuhiro, et al.
Publicado: (2021)

The Impact of Neoadjuvant Hormone Therapy on Surgical and Oncological Outcomes for Patients With Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis
por: Zhang, Lijin, et al.
Publicado: (2021)

Antioxidants and Second Messengers of Free Radicals
por: Zarkovic, Neven
Publicado: (2018)

Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens
por: de Lima, Nelson Gianni, et al.
Publicado: (2013)

Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy
por: Ibeawuchi, Chinyere, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6sdfvr9j8qmlb8bsbtafgtgle9